PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28408884-0	2017	Effect of CYP3A4*1G and CYP3A5*3 Polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects.	Ticagrelor	91-101	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	24-30	
28408884-6	2017	Genetic differences in CYP3A4 and CYP3A5 expression in human volunteers and patients might affect the clearance of ticagrelor or AR-C124910XX in vivo resulting in subsequent variable patient response.	Ticagrelor	115-125	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	34-40	
28408884-7	2017	Thus, this study is designed to explore the effects of CYP3A4*1G and CYP3A5*3 polymorphisms on the pharmacokinetics and pharmcodynamics of ticagrelor in healthy Chinese subjects.	Ticagrelor	139-149	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	69-75	
28408884-8	2017	The results indicated that the CYP3A4*1G polymorphism significantly influenced the pharmacokinetics of AR-C124910XX, and it may be more important than CYP3A5*3 with respect to influencing ticagrelor pharmacokinetics by increasing CYP3A4 activity.	Ticagrelor	188-198	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	151-157